Latest News for: palb2

Edit

What can women with a PALB2 mutation do to their lower risk?

The Pantagraph 21 Oct 2021
In terms of testing, women with the mutation should alternate every six months between breast MRIs and mammograms, according to Perez and Blake. This way, if cancer does start to develop, it can be detected early.Women with the PALB2 mutation ... .
Edit

Does the PALB2 mutation increase a woman’s risk of cancer?

The Pantagraph 21 Oct 2021
The PALB2 mutation is associated with an increased risk of breast cancer, which the Centers for Disease Control and Prevention says is the most common cancer diagnosed in women in the United States, excluding skin cancers. Men can get breast ... .
Edit

Breast cancer risk: What is the PALB2 gene mutation? Expert weighs in

Fox News 13 Oct 2021
Researchers have linked the PALB2 gene mutation to diseases like breast, ovarian and pancreatic cancers ... .
Edit

Global Team of Cancer Genetic Specialists Provides New Guidance for Individuals with PALB2 Gene Variants: ACMG Clinical Practice Resource to Help Guide Clinical Management of Patients at Increased Risk of Breast, Pancreatic and Ovarian Cancers

PR Newswire 11 May 2021
"Management of individuals with germline variants in PALB2 ... PALB2 (Partner and Localizer of BRCA2) germline pathogenic variants are associated with substantially increased breast cancer risk and smaller increased risk for pancreatic and ovarian cancer ... "PALB2 is sometimes ...
Edit

Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

PR Newswire 24 Dec 2020
... or PALB2 mutations. "The FDA's approval of our Phase Ib clinical trial application for testing CX-5461 in patients with BRCA2 or PALB2 mutations is an important milestone and marks a new paradigm in the treatment of cancers with specific pathogenic mutations," stated Dr.
Edit

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

PR Newswire 26 Nov 2020
TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx ... Food and Drug Administration (FDA) and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumors with BRCA2 or PALB2 mutations. "This IND submission is a key milestone in the clinical development of CX-5461 ... .
  • 1
×